# Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

> **NCT00204594** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 1 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** rM28
- **DRUG:** autologous PBMCs

## Key facts

- **NCT ID:** NCT00204594
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00204594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00204594, "Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00204594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*